Baird raised the firm’s price target on Revvity to $127 from $126 and keeps an Outperform rating on the shares. The firm said they reported 1Q revenue in line with and EPS slightly ahead of their model as customer spending caution in pharma/biotech continued, and while the company has seen some encouraging signs of stabilization, it hasn’t yet seen meaningful signs of recovery.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVTY:
- Revvity still sees 2024 non-GAAP EPS $4.55-$4.75, consensus
- Revvity reports Q1 adjusted EPS 98c, consensus 93c
- Early notable gainers among liquid option names on April 9th
- Revvity announces preliminary injunction compelling CSG to comply with contract
- Revvity files complaint against Cloud Software Group, affirms FY24 guidance
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue